Synergy Pharmaceuticals (SGYP) Stock: What Are The Chances Of Recovery? by Lisa Phillips | Mar 1, 2019 12:28 pm | Pharmaceuticals | 0 comments. Join the CNA Finance mailing list below! Is Troy Hamilton's arrival from Shire as Chief Commercial Officer a Trojan Horse maneuver secretly designed to ready Shire's sales force for plecanatide distribution? As mentioned above, Synergy Pharmaceuticals isn’t likely to see an acquisition no matter how bad investors want it to happen. So, insolvency is a concern. Synergy filed for reoganization under Chapter 11 of the U.S. Bankruptcy Code on December 12, 2018 in the Southern District of New York. It’s recent target is Synergy Pharmaceuticals Inc., (NASDAQ: SGYP), a New York City-based biopharma focused on novel gastrointestinal (GI) therapies.Its flagship product, Trulance (plecanatide) is a once-daily tablet approved for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. FUTURES. Save my name, email, and website in this browser for the next time I comment. Notify me of follow-up comments by email. Brian Feroldi | Aug 8, 2017 It was a quiet month for the commercial-stage biopharma, but that didn't stop its shares from tumbling. Since that management departed the troubled company, new management led by former Perrigo CEO Joseph Papa has spent several months putting the finances back in order before making this bid for Synergy. Bausch Health Companies Inc. (NYSE: BHC) is back on the acquisition trail. The software doesn’t look at your... Write CSS OR LESS and hit save. Synergy Pharmaceuticals secures approval for Linzess competitor. Trade Ideas Review: A Deep Dive Into What They Have To... Tradespoon Review: Is The Service Worth Your Money? However, these gains seem to be leading to buyout rumors. In particular, we’re interested in seeing just how high investors push the stock on hopes of a buyout that’s not going to happen. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. CNA Finance encourages all investors to seek professional advice before making any investment decision. Its flagship product, Trulance (plecanatide) is a once-daily tablet approved for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation. Well, I’m here to tell you that’s not the case. It reported inventory issues in November 2014 and saw management turnover soon after as its share price plunged. Futures, Asia mixed as investors ponder the new president. Synergy Pharmaceuticals (SGYP) Stock: Up On Management Update, Sphere 3D (ANY) Stock: The Rainmaker Acquisition Changes The Game, Target Corporation (TGT) Stock: Spiking On Activist Investor Rumors. We’re also tracking TRULANCE sales incredibly closely as well as the continued negotiations with CRG, both of which aren’t going well at the moment, but any positive update may lead to serious gains. This article is exclusive for subscribers. Your email address will not be published. Moving forward, the CNA Finance team will continue to keep a close eye on SGYP. If you want to get in contact with me, leave a comment below or email me at. About: Synergy Pharmaceuticals, Inc. (SGYP) Avisol Capital Partners Long/short equity, newsletter provider, healthcare, biotech Marketplace The Total Pharma Tracker (4,823 followers) Summary Synergy has a good product and poor cash situation. The only rela hope here is that the company will successfully renegotiate the agreement with CRG. Should this goal be missed, the company will have to make a payment in March of next year that it doesn’t have the money to make. Between Friday and today, I doubt that anything has happened to change this. That profit is generated through three (3) different types of relationships. Synergy Pharmaceuticals Inc. is headquartered in New York, New York. This, combined with the more than 60% losses seen on the stock Friday is leading to some tremendous gains. Synergy Pharmaceuticals Inc. (SGYP) NasdaqGS - NasdaqGS Delayed Price. Either way, it doesn’t look good so, let’s hope for a successful renegotiation of the agreement. Couple that with a … Currently (10:40), SGYP is trading at $0.50 per share after a gain of $0.072 per share or 16.63% thus far today. Hey, Im Joshua, the founder of CNA Finance. I was first alerted to this by traffic on CNA Finance leading to an old SGYP buyout rumor. A Synergy Pharmaceuticals (SGYP) Stock Buyout Won’t Happen! Stop wasting your time! CEO Gary S. Jacobs is set to receive a parting bonus of close to $100M should Synergy be sold for $2.8B. The … Bausch announced its cash price was $195 million, still with the assumption of “certain liabilities.” The court was set to review the deal on March 1 and the sale would close shortly after that. Our goal is to bring both news and under discovered stocks to the attention of investors to assist in making smart decisions in the market. TradeMiner Review: Is It Worth Your While? Click to share on Twitter (Opens in new window), Click to share on Facebook (Opens in new window), Magnegas Applied Technology (MNGA) Stock: Up On Acquisition News, Blue Apron (APRN) Stock: Headed Up On Partnership News, Synergy Pharmaceuticals (SGYP) Stock: Climbing On Transaction Closing, Synergy Pharmaceuticals (SGYP) Stock: Tumbling On Acquisition News, Synergy Pharmaceuticals (SGYP) Stock: The Details of the Deal. CNA Finance is a for profit company. (adsbygoogle = window.adsbygoogle || []).push({}); While the buyout rumors circling around Synergy Pharmaceuticals are clearly invalid, they seem to be leading to excitement. Under the terms of the agreement, the company needs to produce just over $61 million in sales from TRULANCE in the year 2018, a goal that the company is on track to miss in a big way. Visitors trend 2W 10W 9M. Bausch Health, formerly known as Valeant Pharmaceuticals International (formerly NYSE: VRX), was a serial acquirer under former management, racking up several deals a year. On December 12, 2018, Synergy Pharmaceuticals Inc. along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York. That became clear on Friday when the company provided a business update. The stock saw some strong gains in the pre-market this morning as it bounced back from losses yesterday. At the time, Salix was a leader in the gastrointestinal market leader with a portfolio of 22 total products. Therefore, while we do everything in our power to provide true, well-researched, and well-thought out opinions, in some instances, a potential conflict of interest may exist. That bodes well for the buyout crowd (which is prominent enough to make “synergy pharmaceuticals buyout” Google’s second suggestion in search).